Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

[{"type":"text","content":"SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidates DZD8586 and DZD6008, have been selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3, 2025, in Chicago.","length":429,"tagName":"p"},{"type":"image","alt":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","displaySize":"","headline":null,"caption":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1u.Z_bHAhdSc0SaTeDpFdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2084187/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In addition, Dizal will present its 4th generation EGFR TKI clinical data in non-small cell lung cancer (NSCLC) during the conference.","length":324,"tagName":"p"},{"type":"text","content":"About DZD8586","length":13,"tagName":"p"},{"type":"text","content":"DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL).","length":196,"tagName":"p"},{"type":"text","content":"While Bruton's Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect lo...

More updates from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A